GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Equity-to-Asset

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Equity-to-Asset : 0.80 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sichuan Goldstone Asia Pharmaceutical's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥2,490 Mil. Sichuan Goldstone Asia Pharmaceutical's Total Assets for the quarter that ended in Mar. 2024 was ¥3,105 Mil. Therefore, Sichuan Goldstone Asia Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.80.

The historical rank and industry rank for Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset or its related term are showing as below:

SZSE:300434' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48   Med: 0.82   Max: 0.91
Current: 0.8

During the past 13 years, the highest Equity to Asset Ratio of Sichuan Goldstone Asia Pharmaceutical was 0.91. The lowest was 0.48. And the median was 0.82.

SZSE:300434's Equity-to-Asset is ranked better than
93.88% of 147 companies
in the Industrial Distribution industry
Industry Median: 0.47 vs SZSE:300434: 0.80

Sichuan Goldstone Asia Pharmaceutical Equity-to-Asset Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Equity-to-Asset Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.81 0.75 0.74 0.77

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.79 0.79 0.77 0.80

Competitive Comparison of Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset

For the Industrial Distribution subindustry, Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset Distribution in the Industrial Distribution Industry

For the Industrial Distribution industry and Industrials sector, Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset falls into.



Sichuan Goldstone Asia Pharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sichuan Goldstone Asia Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2400.43/3101.439
=0.77

Sichuan Goldstone Asia Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=2490.246/3105.395
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Goldstone Asia Pharmaceutical  (SZSE:300434) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sichuan Goldstone Asia Pharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Headlines

No Headlines